This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Merck Hopes Alzheimer's Drug Fares Better Than Competitors

WHITEHOUSE STATION, NJ (TheStreet) -- Alzheimer's patients are in dire need of effective therapies that can slow or even reverse the memory loss and cognitive decline which are the devastating hallmarks of the disease. Unfortunately, recent efforts at developing new drugs have come up short.

Next up will be Merck (MRK), which is expected to release phase II data on its BACE inhibitor by the end of this year, following up on phase Ib data that demonstrated an anti-amyloid effect -- although the trial was conducted in healthy patients and not in Alzheimer's patients.

Of course, investors expectations for Merck's BACE inhibitor are quite low because of the failure of a similar drug developed by Eli Lilly (LLY). In some way, this creates an asymmetric opportunity in that failure (the expected outcome) should have a limited effect on Merck's stock price, whereas success would have an outsized, upside effect. Incyte (INCY) added more than $1 billion to its market value last month after announcing some positive pancreatic cancer data, which illustrates what can happen when a low-expectation clinical trial produces a modicum of success. Merck will not move to the same degree given its current market cap but you get the idea.

In general, BACE inhibitors have low expectations because they are part of the larger beta-amyloid hypothesis that has both dominated the field of Alzheimer's research despite continued failure in the clinic. This past year Pfizer (PFE) and Johnson & Johnson (JNJ) reported a failed phase III trial of their beta amyloid targeting drug bapineuzumab. In addition, Eli Lilly reported what was essentially a failed phase III trial of solanezumab even though the company decided data were good enough to try again with another trial. Why would these failures have less read through to Merck's BACE drug?

Bapineuzumab and solanezumab are both monoclonal antibodies meant to clear beta-amyloid plaques from the brain. These plaques are thought to be more a cause of Alzheimer's as opposed to another symptom. But despite successfully clearing beta-amyloid plaque, neither drug was able to improve cognition or prevent memory loss.

BACE inhibitors work differently by seeking to prevent beta-amyloid plaques from forming. It's a reasonable approach but one which may generate unwanted side effects. Some preclinical work suggests BACE inhibitors might interfere with the formation of myelin, the insulating material around nerves. Lilly halted development of BACE inhibitor trials due to liver toxicity. Whether or not liver toxicity is specific to the Lilly drug or may be a class effect that could also strike Merck's BACE inhibitor isn't known.

It's difficult to predict a successful outcome for Merck's BACE inhibitor study. The odds are stacked against the drug, as they are for all Alzheimer's drugs in development to date. But working in Merck's favor are low expectation and the potential for mega-blockbuster sales if the drug is ever approved. This is just phase II study so a signal of activity, and not complete proof of efficacy, might be enough at this point to move Merck's stock higher.

Sobek has no positions in stocks mentioned in this article.

Stock quotes in this article: MRK, PFE, LLY, JNJ 
David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvnia State Univeristy in 2003 and a BA in international relations from The College of William and Mary in 1997.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs